News
In a study published in the Gold Bulletin journal by a group of researchers from the Center for Applied Physics and Advanced ...
Researchers, led by Dr Rafael T. M. de Rosales and Dr Graeme Stasiuk, have been awarded £10 million in funding from the ...
19h
News Medical on MSNStarfish compound overcomes drug resistance in prostate cancer modelsResearchers identified that triterpene glycosides from the starfish Solaster pacificus can kill drug-resistant prostate ...
20h
Health on MSNPickles vs. Olives: Discover Which Snack Packs More Probiotic PowerFermented pickles and olives can be a source of probiotics, but olives offer more when it comes to nutritional benefits.
Research and development expenses were $12.2 million for the second quarter of 2025, compared to $14.7 million in the same period of 2024. Cash, cash equivalents, and short-term investments totaled ...
A bacteria-based cancer therapy has been engineered that eradicates tumors in immunocompromised mice—no immune cells required.
7h
Tribune Content Agency on MSNEnvironmental Nutrition: Marvelous mangosThe mango fruit is the essence of tropical. Shades of red, orange, yellow, and green surround sunny flesh that may be soft ...
17h
The Brighterside of News on MSNBee venom quickly targets and kills aggressive breast cancer cellsFor centuries, the European honeybee has given people honey, wax, propolis, and even venom. Now, scientists are looking ...
The following is a summary of remarks by Imunon’s President and CEO Stacy Lindborg, PhD. on the second quarter 2025 financial results conference call, provided for Shareholders unable to join the call ...
Imunon Betting on Biomarker Subset to Quickly Bring Immune Boosting Ovarian Cancer Therapy to Market
The OVATION-3 trial is designed to provide an early readout in HRD and BRCA1/2-mutated ovarian cancer patients, ideally leading to rapid filing and approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results